GenomeArc Inc., held the first meeting of its International Scientific Advisory Board (SAB), Eastern Canada time 10am, March 23, 2022.

The meeting brought together for the first time the whole panel of GenomeArc Inc. scientific advisory board (SAB) members, a group of scientists who are leaders on clinical genetic diagnosis, molecular biology and development of genomic drugs. The SAB members and the founder of GenomeArc Inc., a Canadian human geneticist Dr. Mohammed Uddin (Dafil) discussed various aspects of different ongoing genomic and cellular research. The SAB is composed by Professor Wolfgang Kuebler (MD, PhD) Director, Institute of Physiology, Charité - Universitätsmedizin Berlin, Germany Professor, Associate Scientist, University of Toronto, Canada; Professor Proton Rahman, Faculty of Medicine, Memorial University, Canada; Dr. Marc Woodbury-Smith (MD, PhD), Senior Lecturer, Biosciences Institute, Newcastle University, Newcastle Upon Tyne, UK; Dr. Bakhrom K. Berdiev (MD, PhD), Associate Professor, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai.

The objectives of the meeting were fully achieved, and more specifically, evaluating the competitiveness of GenomeArc Inc. technology, the identification of the strategy towards the successful development of ‘GenomeArc Analytics’ application and the design of a genomic drug platform envisaged to allow a proof of concept of this platform in cellular model system in early 2023. The SAB agreed to meet again in a 3-month period to evaluate the evolution of the projects.